Prot # 003-23: A Phase II Randomized, Partially Blinded, Pilot Study to Evaluate the Efficacy and Safety of MK-5172 in Combination with Ribavirin (RBV) in Treatment-Naive (TN) Patients with Chronic Genotype 1 (GT 1) Hepatitis C Virus Infection" MK-5172-03